{"entity":{"id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","aka":[],"tldr":"A phase 3 trial testing Darovasertib in uveal melanoma, now recruiting.","summary":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma is a phase 3 interventional study registered as NCT07804186, led by IDEAYA Biosciences, and recruiting on the registry. Official title: A Randomised, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma. Planned enrolment is 450 participants (estimated). The study started in 2026-09 and primary completion is expected in 2034-03. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07804186","url":"https://clinicaltrials.gov/study/NCT07804186"}],"tags":["ctgov-ingest"],"related":[],"cancers":["uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["darovasertib"],"companies":["ideaya-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07804186","phase":"3","setting":"A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","sponsor":"IDEAYA Biosciences","started":"2026-09","startedType":"estimated","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07804186/","neighbours":{"cancer":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"drug":[{"id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/"}],"company":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/"}]}}